穿刺前阴性磁共振成像下漏诊临床显著前列腺癌的预测因素:系统综述与荟萃分析
该系统综述与荟萃分析检索MEDLINE和Scopus至2019年3月,纳入16项研究,评估前列腺癌初治患者穿刺前阴性磁共振成像后临床显著前列腺癌的预测因素。前列腺特异性抗原密度(PSAD)是研究最充分且最强的预测因素;8项研究(1015例)荟萃分析显示,PSAD<0.15 ng/ml/ml联合磁共振成像使总体阴性预测值从84.4%升至90.4%。
要点
- PSAD是穿刺前阴性磁共振成像患者漏诊临床显著前列腺癌的最强预测因素。
- PSAD<0.15 ng/ml/ml联合磁共振成像使总体阴性预测值从84.4%升至90.4%。
- 该联合策略有助于识别可避免穿刺的临床显著前列腺癌低风险男性。
核心结论
- 穿刺前阴性磁共振成像时,PSAD<0.15 ng/ml/ml是识别可避免穿刺且无临床显著前列腺癌男性的最有用因素。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE和Scopus至2019年3月,方案注册于PROSPERO(CRD42019125549),共16项研究符合纳入标准。
主要发现
- PSAD是穿刺前阴性磁共振成像男性中研究最充分且最强的临床显著前列腺癌预测因素。
- 8项研究(1015例)符合荟萃分析,评估PSAD<0.15 ng/ml/ml联合磁共振成像对减少漏诊临床显著前列腺癌风险的附加价值。
- 联合PSAD后,总体磁共振成像阴性预测值从前列腺癌初治患者的84.4%升至90.4%。
- 阴性预测值在活检初治亚组从82.7%升至88.7%,在既往阴性活检亚组从88.2%升至94.1%。
关键数值与推荐
- PSAD阈值为<0.15 ng/ml/ml,联合穿刺前阴性磁共振成像用于预测临床显著前列腺癌。
- 联合PSAD<0.15 ng/ml/ml后,总体磁共振成像阴性预测值从84.4%升至90.4%。
- 活检初治亚组阴性预测值从82.7%升至88.7%,既往阴性活检亚组从88.2%升至94.1%。
临床怎么用
- 对穿刺前磁共振成像阴性且PSAD<0.15 ng/ml/ml的前列腺癌初治男性,可考虑避免穿刺。
局限性
- 报告磁共振成像联合标志物阴性预测值的研究较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We systematically reviewed the literature on predictive factors for clinically significant prostate cancer diagnosis after prebiopsy negative magnetic resonance imaging in prostate cancer naïve patients. MATERIALS AND METHODS: The MEDLINE® and Scopus® databases were searched up to March 2019. The review protocol was published in the PROSPERO database (CRD42019125549). The clinical factors and markers studied were age, prostate specific antigen, prostate specific antigen isoforms, prostate specific antigen density, PCA3, prostate volume, family history, ethnicity and risk calculators. The primary objective was to determine their predictive ability for clinically significant prostate cancer diagnosis. Secondary objectives included meta-analysis of the negative predictive value of prebiopsy negative magnetic resonance imaging when combined with these predictive factors. RESULTS: A total of 16 studies were eligible for inclusion. Few studies reported negative predictive value of magnetic resonance imaging combined with a marker. Prostate specific antigen density was the best studied and the strongest predictor of clinically significant prostate cancer in men with prebiopsy negative magnetic resonance imaging. There were 8 studies (1,015 patients) eligible for meta-analysis of the added value of prostate specific antigen density less than 0.15 ng/ml/ml to magnetic resonance imaging in reducing the risk of missing clinically significant prostate cancer. When combined with prostate specific antigen density, overall magnetic resonance imaging negative predictive value increased from 84.4% to 90.4% in cancer naïve patients. The increase was from 82.7% to 88.7% in biopsy naïve and from 88.2% to 94.1% in previous negative biopsy subgroups. CONCLUSIONS: The use of prostate specific antigen density less than 0.15 ng/ml/ml in the presence of prebiopsy negative magnetic resonance imaging was the most useful factor to identify men without clinically significant prostate cancer who could avoid biopsy.
引用
- Pagniez MA, Kasivisvanathan V, Puech P, et al. Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. J Urol. 2020. PMID: 31967522. doi:10.1097/JU.0000000000000757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。